Cicor Technologies (CICN) H2 2024 earnings summary

Executive summary

• Achieved record proforma sales above CHF 500 million and proforma EBITDA above CHF 60 million, marking the best results in company history for 2024.

• EPS surged to CHF 6.20, and EBITDA reached CHF 58.4 million, reflecting top-tier profitability.

• Maintained focus on high-value markets: healthcare technology, industrial, aerospace, and defense, avoiding commoditized sectors.

• Four acquisitions in 2024 drove significant value, boosting market share and operational scale.

• Strategy 2028 aims to establish leadership in core markets and continued growth.

Financial highlights

• Revenue up 23.3% year-over-year to CHF 480.8 million; EBITDA up 29.3% to CHF 58.4 million.

• Net profit and EPS more than doubled to CHF 6.20, up 134% year-over-year.

• Free cash flow reached a record CHF 61.1 million, up 132% from the previous year.

• Net debt stable at CHF 44 million; leverage reduced to 0.74.

• ROIC increased to nearly 15%; equity ratio stood at 32.8%.

Outlook and guidance

• 2025 guidance: sales of CHF 520–560 million, with EBITDA margin expected to remain at current levels.

• Anticipates low to mid-single-digit organic growth, with further strengthening of the Swiss franc.

• Potential acquisition of Éolane France could add CHF 125 million in profitable sales, not included in current guidance.

• Midterm targets: organic growth of 7–10% per year, revenue above CHF 1 billion, EBITDA margin 10–13%, and ROIC above 15% by 2028.

• No dividends planned while growth opportunities persist.